Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 for moderate to severe inflammatory acne (Phase 2, randomized, placebo-controlled)
2017-003191-30Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LYS006 in inflammatory acne, acne vulgaris, sponsored by Novartis. Started May 2018; status: completed.
02
Drugs
LYS006
03
Conditions
inflammatory acneacne vulgaris
Beyond the preview
Go deeper on 2017-003191-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003191-30.